Autism spectrum disorders (ASDs) comprise a highly heritable, multifarious group of neurodevelopmental disorders, which are characterized by repetitive behaviors and impairments in social interactions. Point mutations have been identified in X-linked Neuroligin (NLGN) 3 and 4X genes in patients with ASDs and all of these reside in their extracellular domains except for a single point mutation in the cytoplasmic domain of NLGN4X in which an arginine is mutated to a cysteine (R704C). Here we show that endogenous NLGN4X is robustly phosphorylated by protein kinase C (PKC) at T707, and R704C completely eliminates T707 phosphorylation. Endogenous NLGN4X is intensely phosphorylated on T707 upon PKC stimulation in human neurons. Furthermore, a phosphomimetic mutation at T707 has a profound effect on NLGN4X-mediated excitatory potentiation. Our results now establish an important interplay between a genetic mutation, a key posttranslational modification, and robust synaptic changes, which can provide insights into the synaptic dysfunction of ASDs.n a 2014 report published by the Centers for Disease Control and Prevention (CDC), it was estimated that 1 in 68 children in the United States have an autism spectrum disorder (ASD) (1). These neuropsychiatric disorders have a strong genetic component consistent with high recurrence rates between siblings and a higher concordance frequency seen in monozygotic than dizygotic twins. Furthermore, deletions, insertions, and substitutions have been identified within the genome that increase the risk of these disorders (2, 3). These cytogenetic and genome sequencing studies have revealed that Neuroligins (NLGNs) are one of a subset of genes encoding synaptic proteins associated with ASDs (4, 5).The NLGN gene family consists of five members (Nlgn1, 2, 3, 4X, and 4Y) within the human genome that encode transsynaptic cell adhesion molecules that are critical for synapse assembly, maintenance, and plasticity (5-7). Numerous studies have identified a variety of mutations in X-linked NLGN3 and 4X genes that range from copy number variants (8-11) to protein truncations and amino acid substitutions in patients with ASDs (4,12,13). Interestingly, all of the point mutations in NLGN3 and NLGN4X reside in their extracellular domains except for a single point mutation in the cytoplasmic domain (c-tail) of NLGN4X at arginine (R) 704, which is modified to a cysteine (C) (14). How this mutation or other NLGN disease mutations contribute to the pathophysiology is unknown.Protein phosphorylation is a critical modulator of NLGN function (15, 16). Recently, we showed that Ca 2+ /CaM kinase II (CaMKII) phosphorylates the c-tail of NLGN1 in an isoform-specific and activity-dependent manner, which regulates its ability to enhance excitatory synapses (16). Next, we wondered if different kinases might regulate the function of other NLGN isoforms?In the present study, we show in vitro and in vivo that NLGN4X is robustly phosphorylated by protein kinase C (PKC).We identified the dominant phosphorylation site as...